OBJECTIVES: Hunter syndrome (HS) is a rare X-linked progressive multi-systemic lysosomal storage disease. The 55 item child and 68 item parent versions of the 8 domain HS-FOCUS questionnaire were used to monitor the safety and efficacy with enzyme replacement therapy (ERT) in clinical trials. The objective was to validate HS-FOCUS according to the FDA PRO Guidance. METHODS: HS-FOCUS data collected in a placebo-controlled trial (53 weeks, plus 36 months extension) were used to evaluate item performance, reliability, validity, and responsiveness. RESULTS: Altogether, 55 children and 84 parents completed the HS-FOCUS at baseline and follow up visits. High percentage of lowest item response (Ͼ 60%) and high average inter-item correlations suggested that some items were less informative or redundant. The internal consistency met the Ͼ0.70 criteria for all domains in parents and children, except the breathing domain in children. The test-retest reliability was Ͼ0.70 for Walking/Standing, School/Work, Activities, and Overall Function domains in parents, and for Walking/Standing and Activities domains in children. The construct validity correlating the HS-FOCUS with Childhood Health Assessment Questionnaire (CHAQ) showed moderate to high correlations in related concepts, especially in activity related domains. Correlations with lung function (FEV1) ranged from -0.06 (School/Work) to -0.48 (Breathing). Significantly score differences were found in most domains among tertiles based on overall-well being and pain VAS. Responsiveness showed large effect sizes, especially for Sleep, Breathing and School/work domains (0.50-1.07). CONCLUSIONS: Developing disease-specific PROs for rare diseases is challenging due to the nature of the evidence base. This study demonstrates HS-FOCUS to be a reliable, valid, and responsive instrument which can be applied in clinical trials or disease registries. The questionnaire can be streamlined by reducing item redundancy without compromising its validity. Simultaneously, an item bank may be generated which could serve as a basis for developing questionnaires for other mucopolysaccharidosis disorders.
OBJECTIVES:
The PedsQL™ Measurement Model is a modular approach to measuring health-related quality of life (HRQOL) in healthy children and adolescents and those with acute and chronic health conditions. Several Spanish versions for use in different Spanish speaking countries were developed. The objectives of this study were to compare these Spanish versions, quantify and qualify the differences and conclude on the need (or not) for country-specific Spanish versions. METHODS: Our study focused on the Teen form (13-18) and included the following steps: 1.Collection of the validated Spanish versions in collaboration with the author; 2.Identification of the differences in items, and response scales; and 3. Coding of the differences as Cultural (C), Lexical (L), Idiomatic (I) and Syntactical (S). RESULTS: Six validated Spanish versions were retrieved: Spanish for US, Spain, Argentina, Chile, Mexico and Peru. Since it was the first translated, the US Spanish version served as comparator. All versions showed differences. Spanish for Spain showed the highest number of differences (57), then Chile (47), Argentina (36), Peru (20) and Mexico (18). None of the differences were cultural. In 65% of the cases, the divergences were idiomatic. For instance, the expression "Se me hace difícil" (It is hard for me) used in US Spanish was replaced in all corresponding items by "Me cuesta" (Literally "It costs me") in Spain, Argentina and Chile. The time recall sentence and item 3 of the School Functioning Scale showed most of the differences. One of the reasons could be the use of a very idiomatic form in the original US English version: "I have trouble keeping up". It should be noted that items of the Emotional Functioning Scale showed very few differences. CONCLUSIONS: Numerous changes in wording for idiomatic reasons indicating respondents preferences point to the necessity of developing specific Spanish versions of the PedsQL™.
PIH42 PATIENTS WITH URINARY DISORDERS, EVOCATIVE OF BPH: WHAT ARE THEIR EXPECTATIONS IN FRANCE, IN ITALY AND IN PORTUGAL?
Perrin P 1 , Auges M 2 , Rahhali N 2 , Taieb C 2 1 Lyon Sud, Pierre Benite, France, 2 PFSA, Boulogne Billancourt, France OBJECTIVES: The individualised expectations of the patient will undoubtedly be one of the major preoccupations in the next few decades to guarantee optimal treatment through compliance. METHODS: A pragmatic, European cohort (France, Italy, and Portugal) of 477 patients presenting with urinary disorders, evocative of BPH, was followed-up over 6 months. A questionnaire regarding expectations was handed out at the first consultation. RESULTS: A total of 441 patients were evaluated. The symptom that 31,11% of patients wished to see improved with the highest priority were "getting up in the night to urinate", then for 20%, "sensation of not emptying the bladder after urinating Љ. Amongst the symptoms that patients were the least concerned about were Љthe effort or force needed to start urinatingЉ for 26,80% of responders, then "size and force of the stream of urineЉ for 15,38% and Љthe interruption of the flow of urineЉ for 13,40%."Getting up in the night" was the principal complaint in all 3 countries (36,30% in France, 29 and 27,54% in Portugal and Italy), whereas Љthe effort or force needed to start urinatingЉ is the symptom that preoccupies the patients the least in France and Italy, and the "size and force of the stream of urine" preoccupies the Portuguese the least.Nearly 87% of the Italians claimed that they would only be satisfied if they never had to get up in the night again, (35% for the French, 67% for the Portuguese).Overall, 60% of the subjects questioned said that they would be satisfied if they were "markedly" improved. CONCLUSIONS: The expectation of patients in the treatment of BPH is very important, and undoubtedly difficult to satisfy entirely. These results are probably due to the fact that our population was composed of patients that had been diagnosed recently. (2006). Academic achievement, a scale of the Child Health and Illness Profile (CHIP), was collected at follow-up. Data on gender and family socio-economic status was also collected. Multivariate linear regression analysis was performed to assess the influence of changes in health-related behaviours on academic achievement and HRQOL controlling for socioeconomic and family factors. RESULTS: Response rate at follow-up was 54% (nϭ454). Twenty six percent of the sample reported ever use of tobacco, while 4.6% reported to have started or to be a current regular smoker at follow-up; 18% reported starting or increasing alcohol consumption, and 16.5% on substance consumption (mainly cannabis). Preliminary multivariate analyses show that becoming a current smoker during the follow-up period was associated to worse Academic achievement among girls (beta coefficientϭ-5.0; pϭ 0.02); reporting ever drug consumption was associated with worse Psychological well-being among girls (betaϭ -3.1; pϭ0.04), and with worse Physical well-being among boys (betaϭ -5.9; pϭ0.004), at the follow-up. CONCLUSIONS: Changes in healthrelated behaviours are associated with worse outcome at 3 years of follow-up. Future studies should analyse factors related to susceptibility for regular use of tobacco and other drugs. Policy initiatives, and other factors should be taken into account preventing tobacco and other substance use at these ages.
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HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS WITH CHRONIC CONDITIONS: REVEALING THE PROFILE OF BURDEN ASSOCIATED WITH CO-MORBID PHYSICAL AND MENTAL CONDITIONS IN RESPONDENTS FROM FIVE EUROPEAN COUNTRIES
Rendas-Baum R 1 , Smith KJ 1 , DiBonaventura MD 2 , Bayliss MS 1 , Alonso J 3 , Ferrer M 4 , Vilagut G 5 1 QualityMetric Incorporated, Lincoln, RI, USA, 2 Kantar Health, New York, NY, USA, Barcelona, Spain, Spain, Barcelona, Barcelona, Spain, 5 IMIM (Institut de Recerca Hospital del Mar) , Barcelona, Catalunya, Spain OBJECTIVES: Studies often examine the impact of specific chronic conditions (CC) in isolation or in conjunction with another specific CC. Our aims were to compare: 1) the effect of physical CCs (PCC) in addition to mental CCs (MCC) to the effect of PCCs only; 2) the effect of MCCs in addition to PCCs to the effect of MCCs only; and 3) effects across country. METHODS: Data from the 2010 EU National Health and Wellness Survey were used (Nϭ57,805; France, Germany, Italy, Spain, and the UK). Respondents were categorized as: 'Healthy' (no mental or physical CC); 'Physical' (physician indicated 1ϩ physical but no mental CCs); 'Mental' (physician indicated 1ϩ mental but no physical CCs); 'Physical and Mental' (1ϩ mental and 1ϩ physical CCs). Differences across groups were assessed using multivariate regression with SF-12v2 ® Health Survey summary measures (PCS & MCS) as outcomes and controlling for age and gender. RESULTS: Relative to 'Healthy' respondents, the presence of 1ϩ PCC was associated with a significant decrement in both PCS (-3.04 to -5.18, pϽ.05) and MCS (-1.23 to -2.53, pϽ.05). The presence of 1ϩ mental condition was also associated with decreased MCS (-7.10 to -13.30, pϽ.05) and PCS (-1.23 to -2.53, pϽ.05). Interestingly, the impact of co-morbid conditions, physical or mental, varied as a function of other existing conditions (physical or mental). The impact of adding 1ϩ PCC to an existing MCC was associated with a larger decrement in PCS (-4.34 to -6.92, pϽ.05) and MCS (-8.54 to -11.70, pϽ.05 ) as compared to adding 1ϩ PCC to those who were healthy. Results were consistent across gender and country. CONCLUSIONS: These findings (which are largely consistent an earlier US study) highlight the complexity of managing patients with co-or multi-morbid CCs as the measurable burden of CCs varies with the presence of other conditions.
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BURDEN OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA: FINDINGS FROM A CROSS-SECTIONAL PATIENT REPORTED OUTCOMES STUDY
